Last reviewed · How we verify
Estrogen patch
At a glance
| Generic name | Estrogen patch |
|---|---|
| Also known as | Climara, Estraderm, Vivelle-Dot®, Estradiol cream, Premarin Cream® |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Menopausal Hormones and Sympathetic Activation (PHASE4)
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Estradiol Supplementation and Rotator Cuff Repair (PHASE2)
- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial (PHASE2)
- Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estrogen patch CI brief — competitive landscape report
- Estrogen patch updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI